How to Read a Flow Cytometry Report

A flow cytometry report is a lab document that describes individual cells in a sample, usually blood or bone marrow, by their size, internal complexity, and the proteins on their surface. It translates laser-based measurements of thousands or millions of cells into a clinical picture your doctor can use to diagnose blood cancers, monitor immune function, or track treatment response. The report typically includes plots (visual graphs of the data), a list of cell-surface markers with their expression levels, percentage breakdowns of different cell populations, and a narrative interpretation. Reading one yourself can feel like decoding a foreign language, but the core logic is surprisingly straightforward once you know what each piece represents.

What the Plots Are Showing You

Most flow cytometry reports include one- or two-parameter plots that display data from the instrument’s measurements. A one-parameter histogram looks like a simple mountain graph: the horizontal axis represents the intensity of a particular measurement (say, the brightness of a fluorescent marker), and the vertical axis shows how many cells had that intensity. A two-parameter plot, often called a dot plot or density plot, maps two measurements against each other so that every dot represents a single cell positioned according to two characteristics at once. These are the workhorses of flow cytometry data analysis.¹

The two measurements you will see most often on initial plots are forward scatter (FSC) and side scatter (SSC). Forward scatter roughly corresponds to cell size: larger cells deflect more light forward. Side scatter reflects internal complexity, meaning how granular or packed with structures a cell’s interior is. A small, smooth lymphocyte will sit low on both axes, while a larger, granular neutrophil lands higher. This FSC-versus-SSC plot is usually the first thing in the report because it gives a crude map of the major cell populations before any staining is considered.

What Gating Means

Gating is the process of drawing boundaries around clusters of cells on these plots to isolate specific populations for further analysis. Think of it like circling groups on a scatter chart. A technician or pathologist might first draw a gate around the lymphocyte cloud on the FSC/SSC plot, then look only at those gated lymphocytes on a second plot that measures specific surface markers. Each subsequent gate narrows the focus further, moving from “all white blood cells” to “T cells” to “helper T cells” and so on.

This stepwise narrowing is called a gating hierarchy, and it is both the backbone of flow cytometry analysis and one of its biggest sources of variability. Because gates are traditionally drawn by hand, two experienced operators can draw slightly different boundaries and get slightly different percentages. For large experiments with many markers, the time required for manual gating and the variability it introduces can become substantial.² Your report’s percentages are the product of wherever those gates were placed, which is why small shifts between sequential reports do not always mean your cells have changed.

Quality Control Notes Worth Understanding

Before the clinical results mean anything, the lab has to deal with several technical artifacts. Reports from thorough labs will mention these steps, and knowing what they are helps you judge the report’s reliability.

Compensation

Flow cytometers use multiple fluorescent dyes at once, each designed to glow at a different wavelength. The problem is that dyes are not perfectly tidy: a dye meant to shine green might also leak a little signal into the detector for yellow. Compensation is the mathematical correction that subtracts this spillover so that each detector’s reading reflects just one dye. Done correctly, it is invisible. Done poorly, it creates false-positive signals that can make a cell population appear to express a marker it does not actually carry.³

Doublet Discrimination

Sometimes two cells pass through the laser beam stuck together, and the instrument reads them as one abnormally large event. These doublets can contaminate results, making it look like there are cells with unusual marker combinations that do not actually exist. Labs identify doublets by comparing different properties of the signal pulse, most commonly forward-scatter area versus forward-scatter height. A single cell produces a proportional area-to-height relationship; a doublet does not.⁴ If your report includes a “singlets gate,” that is where doublets were removed.

Viability Staining

Dead cells are a nuisance in flow cytometry. Their membranes are damaged, so fluorescent antibodies can leak inside and stick to internal proteins, creating bright but meaningless signals. Viability dyes exploit this: they bind weakly to the surface of intact living cells but flood into dead cells and stain them brightly. The lab then gates out these brightly stained dead cells before analyzing anything else.⁵ If the report mentions a viability gate or “live cell gate,” that is the step responsible.

What CD Markers Mean on Your Report

The heart of most clinical flow cytometry reports is a table or list of CD markers, short for “cluster of differentiation.” Each CD number refers to a specific protein found on the cell surface, and different cell types carry different combinations. CD3 marks T cells. CD19 and CD20 mark B cells. CD4 identifies helper T cells; CD8 identifies cytotoxic T cells. CD34 appears on immature stem cells. These are not exotic codes invented to confuse patients. They are the molecular name tags that identify which kind of immune cell you are looking at.

On a clinical report, each marker is usually reported as the percentage of cells that are positive for it, sometimes accompanied by the intensity of expression described as strong (bright), dim (weak), or negative. A standardized reporting format may describe the extent of infiltration by an abnormal cell population, then characterize antigen expression as strong, weak, or negative, followed by a diagnostic conclusion.⁶ So if your report says “CD20 bright, CD5 weak positive, CD23 positive,” it is describing the surface-marker fingerprint of a particular cell population. The pathologist then matches that fingerprint against known profiles for various diseases.

Expression intensity matters, not just whether a marker is present. A population of cells that is “CD10 dim” is biologically different from one that is “CD10 bright,” and this distinction can change the diagnosis. When reading your report, pay attention to qualifiers like dim, partial, aberrant, or subset-positive. These nuances often carry as much diagnostic weight as the simple positive-or-negative calls.

CD45 and Side Scatter in Leukemia Workups

If your report is from a leukemia evaluation, you will almost certainly see a CD45-versus-SSC plot. CD45 is a protein found on virtually all white blood cells, but different cell types express it at different levels. Mature lymphocytes are CD45-bright, monocytes are intermediate, granulocytes are moderate with high side scatter, and leukemic blast cells tend to be CD45-dim with low side scatter. This creates a natural separation on the plot that makes blasts easier to identify than on a basic FSC/SSC plot alone.

A study of 74 cases of acute myeloid leukemia found that the percentage of blast cells identified by CD45/SSC gating correlated much more closely with what pathologists saw under the microscope than blast counts from conventional FSC/SSC gating. The correlation with microscopy was 0.94 for CD45/SSC gating compared with 0.76 for FSC/SSC gating, because the physical size and granularity of blasts often overlap with normal cells, while the CD45 intensity does not.⁷ If your report mentions “CD45/SSC gating” or shows a plot labeled this way, that is the preferred method for finding abnormal blast populations.

Light Chain Restriction and Lymphoma

For suspected B-cell lymphomas, one of the most important findings on a flow cytometry report is whether the B cells show light chain restriction. Normal B cells produce a mix of two types of antibody light chains, called kappa and lambda, in a rough natural ratio. A malignant B-cell population, having all descended from a single cancerous cell, will overwhelmingly produce just one type. When the report says “kappa-restricted” or “lambda-restricted,” it means the B cells are clonal, which strongly supports a lymphoma diagnosis.

However, light chain restriction is not a perfect test. A study of diffuse large B-cell lymphoma (DLBCL) cases found that about a quarter of them did not show light chain restriction by flow cytometry.⁸ This means a negative result does not rule out lymphoma. Some large B-cell lymphomas simply do not express enough surface immunoglobulin for flow cytometry to detect the restriction. This is a case where the pathologist integrates the flow data with biopsy findings, imaging, and clinical context rather than relying on flow cytometry alone.

CD4 Counts and Immune Monitoring

Outside of cancer, the most widely recognized use of flow cytometry is measuring CD4 T-cell counts for monitoring HIV infection and other immunodeficiency conditions. A normal CD4 count in adults is roughly 500 to 1,500 cells per microliter, and the report will usually give both an absolute count (cells per microliter) and a percentage of total lymphocytes. If you are following CD4 counts over time, small fluctuations between visits are normal and often reflect the time of day, stress, or minor infections rather than a meaningful change in immune status.

Validation studies have confirmed that different flow cytometry platforms produce closely agreeing CD4 results. A comparison between two platforms in a field setting showed correlations above 0.92, with close agreement in both absolute counts and percentages.⁹ This is reassuring if you have been tested on different machines at different facilities: the numbers should be comparable.

Why Reference Ranges Are Not One-Size-Fits-All

One of the most common sources of confusion when reading a flow cytometry report is comparing your numbers against “normal” ranges. Reference intervals for immune cell subsets vary by age, sex, and ethnicity. A study comparing Asian and non-Asian adults found that the Asian population had lower mean percentages of CD3 and CD4 cells, a lower CD4/CD8 ratio, and lower absolute CD4 counts.¹⁰ A person from a population with naturally lower baseline CD4 counts might appear borderline on a reference range derived from a different population, even if their immune function is perfectly normal.

Age adds another layer of complexity, especially in children. Pediatric reference values for lymphocyte subsets differ substantially from adult ranges and shift during the first years of life. A recent effort to establish pediatric reference ranges for extended immunophenotyping found considerable variability in how different published studies defined lymphocyte subsets and analyzed their statistics, making direct comparisons between reports from different labs challenging.¹¹ If your child’s report flags a value as outside the reference range, ask whether the range was derived from age-matched children or from adults.

Specimen Quality and Hemodilution

Not all samples are created equal, and specimen quality can meaningfully affect the numbers on your report. Bone marrow aspirates, in particular, are vulnerable to hemodilution: the longer the needle sits in the bone, the more peripheral blood gets mixed in with the marrow sample. Sequential pulls from the same patient show decreasing proportions of blast cells in later specimens because each pull draws in more blood and less actual marrow. Researchers have proposed formulas that normalize the aspirate to the expected composition of uncontaminated marrow, correcting for this dilution effect.¹²

If your bone marrow flow cytometry report mentions “hemodilute” or notes that the specimen quality was suboptimal, that is a flag that the blast percentages or other marrow-specific numbers may underestimate the true values. The pathologist will typically note this and may recommend repeating the aspirate or relying more heavily on the biopsy and morphologic examination for the final assessment. A report that identifies only 3% blasts in a hemodilute sample might actually come from a marrow with 15% blasts, so context matters enormously.

Minimal Residual Disease Testing

For patients being treated for leukemia, flow cytometry reports sometimes include minimal residual disease (MRD) results. MRD testing looks for tiny numbers of cancer cells left behind after treatment, at levels far below what a microscope can see. The sensitivity of flow-based MRD testing can reach roughly 1 in 10,000 cells (written as 10⁻⁴ in scientific notation), meaning it can detect one leukemia cell among ten thousand normal ones.¹³

An MRD result is usually reported as either “positive” or “negative” at a specified sensitivity level, sometimes with a quantitative estimate (for example, “MRD positive at 0.03%”). “MRD negative” is good news but comes with a caveat: the test can only say that no leukemia was detected down to that sensitivity limit. If the sensitivity only reached 10⁻³ rather than 10⁻⁴ due to technical factors like a low cell count in the sample, a negative result is less reassuring. Always check the stated sensitivity alongside the MRD result. The technique also requires experienced technicians to set the gates correctly, and achieving the full sensitivity of 10⁻⁴ is not guaranteed in every run.

Spectral Flow Cytometry and What It Changes

Traditional flow cytometers assign one detector to each fluorescent dye. Spectral flow cytometers, increasingly common in both research and clinical labs, use a larger number of detectors than the number of dyes in the experiment. Instead of subtracting spillover through conventional compensation, spectral instruments capture the full emission spectrum of each dye and use mathematical unmixing to separate the signals.¹⁴ For the patient reading a report, the practical consequence is that spectral instruments can measure more markers simultaneously, which can mean a more complete picture of your cells from a single tube of blood.

You probably will not see “spectral” stamped on a clinical report, but you might notice unusually large panels with 20 or more markers measured at once. The underlying data processing is different from traditional compensation, though the final report format should look familiar: populations identified, markers scored as positive or negative, percentages and intensities listed.

Automated Gating and Its Growing Role

The traditional approach of drawing gates by hand is slowly being supplemented or replaced by computational methods. Automated gating pipelines that rely heavily on built-in controls for population discrimination have been shown to analyze large-scale clinical datasets with comparable precision and accuracy to manual gating.¹⁵ More recent approaches use machine-learning models that have demonstrated high accuracy with short computing times.¹⁶

One particular challenge in automated analysis is batch effects, where results shift slightly depending on the day the sample was run, the lot of reagents used, or instrument calibration differences. A system called UNITO, designed to handle automated gating through image-based segmentation of bivariate plots, has shown robustness to these variations without needing extra preprocessing steps, making it a promising tool for high-throughput clinical environments.¹⁷ For you as a patient, this trend means reports generated in the future will likely have less operator-dependent variability. A gate drawn by a validated algorithm is the same gate every time, which should make serial comparisons between your reports more reliable.

Practical Tips for Reading Your Own Report

When you receive a flow cytometry report, start with the narrative interpretation at the end. The pathologist’s summary synthesizes all of the plots, percentages, and marker data into plain clinical language. If your report lacks a narrative and gives only raw data, ask your ordering physician for an interpretation, because the numbers alone require expertise to contextualize.

A few things to look for as you read through the body of the report:

Specimen type and quality: Was it blood, bone marrow, a lymph node, or fluid from the body? Was the sample noted as hemodilute or low in cellularity? These details affect how much you should trust the percentages.
Viability: If reported, check that a reasonable proportion of cells were alive. A low viability percentage (say, under 70%) can compromise all downstream results.
Abnormal populations: Look for language identifying an “aberrant” or “atypical” population. The report should describe what markers that population expresses and what percentage of total cells it represents.
Marker intensity: Strong versus dim expression of the same marker can point to entirely different diagnoses. If CD20 is listed as “dim,” that carries different clinical meaning from “bright.”
Reference ranges: If absolute counts are provided alongside percentages, check whether the reference range matches your demographic. Ask your doctor if the range accounts for your age, sex, and ethnicity.

Do not panic over isolated abnormalities. Flow cytometry is one piece of a larger diagnostic puzzle. A single marker that reads slightly outside the reference range, or a small population that looks mildly unusual, may mean nothing when combined with your clinical picture, blood counts, and imaging. Conversely, do not ignore a report that says “no evidence of abnormal population” if you have other concerning symptoms. As the lymphoma data showed, flow cytometry can miss certain diseases. The clinician’s job is to weigh the flow report alongside everything else, and that integration is where the real diagnosis happens.